Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Targeting of molecular pathways involved in the cell-to-cell propagation of pathological tau species is a novel approach for development of disease-modifying therapies that could block tau pathology and attenuate cognitive decline in patients with Alzheimer's disease and other tauopathies. We discovered cambinol through a screening effort and show that it is an inhibitor of cell-to-cell tau propagation. Our in vitro data demonstrate that cambinol inhibits neutral sphingomyelinase 2 (nSMase2) enzyme activity in dose response fashion, and suppresses extracellular vesicle (EV) production while reducing tau seed propagation. Our in vivo testing with cambinol shows that it can reduce the nSMase2 activity in the brain after oral administration. Our molecular docking and simulation analysis reveals that cambinol can target the DK-switch in the nSMase2 active site. Copyright © 2018 Elsevier Inc. All rights reserved.

Citation

Tina Bilousova, Chris Elias, Emily Miyoshi, Mohammad Parvez Alam, Chunni Zhu, Jesus Campagna, Kanagasabai Vadivel, Barbara Jagodzinska, Karen Hoppens Gylys, Varghese John. Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2. Biochemical and biophysical research communications. 2018 May 23;499(4):751-757

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 29604274

View Full Text